EP Patent

EP0618803A4 — Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments.

Assigned to Texas Biomedical Research Institute · Expires 1995-03-22 · 31y expired

What this patent protects

Patent listed against osilodrostat-phosphate.

Drugs covered by this patent

osilodrostat-phosphate (OSILODROSTAT PHOSPHATE)

Patent Metadata

Patent number: EP0618803A4
Jurisdiction: EP
Classification: —
Expires: 1995-03-22
Drug substance claim: No
Drug product claim: No
Assignee: Texas Biomedical Research Institute
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.